Lancashire and South Cumbria
Formulary
Formulary
3 Respiratory system
When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified
03-03-02 Leukotriene receptor antagonists
| Montelukast |
|
Formulary
|
Tablets 10mg (for patients over 15 years of age) Chewable tablets 5mg (for patients 6-14 years of age) Chewable tablets 4mg (for patients aged 2-5years of age) Granules 4mg (for patients 6months to 5 years) |
 LSCMMG: Asthma Treatment Guideline for Adults (aged 17 and over) LSCMMG: Asthma Treatment Guideline for Children MHRA: Montelukast: reminder of the risk of neuropsychiatric reactions |
|
Links
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
- Asthma action plan child: Asthma UK
- Asthma management plan: Asthma UK
- LSCMMG: Asthma Treatment Guideline for Adults
- LSCMMG: Asthma Treatment Guideline for Adults (aged 17 and over)
- LSCMMG: Asthma Treatment Guideline for Children
- LSCMMG: Asthma Treatment Guideline for Children
- LSCMMG: COPD Desktop Guideline
- MART asthma plan
- MHRA Drug Safety Update :Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
- MHRA: Montelukast: reminder of the risk of neuropsychiatric reactions
- MHRA: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects
- NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence
- NICE NG80:Asthma: diagnosis, monitoring and chronic asthma management
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)